Characteristically, NSCLC may develop resistance to therapy by driver mutations in EGFR, BIM, KRAS, MET, and HER2 that alter downstream signaling, allowing the tumors to bypass the upstream tyrosine kinase-targeted therapy (304). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.